138 related articles for article (PubMed ID: 25407112)
1. Successful re-administration of lenalidomide after lenalidomide-induced pulmonary alveolar hemorrhage in a patient with refractory myeloma.
Sakai M; Kubota T; Takaoka M; Tsukuda T; Arakawa Y; Anabuki K; Ikezoe T; Togitani K; Yokoyama A
Ann Hematol; 2015 May; 94(5):891-2. PubMed ID: 25407112
[No Abstract] [Full Text] [Related]
2. Diffuse alveolar hemorrhage associated with lenalidomide.
Sakai M; Kubota T; Kuwayama Y; Ikezoe T; Yokoyama A
Int J Hematol; 2011 Jun; 93(6):830-831. PubMed ID: 21573890
[No Abstract] [Full Text] [Related]
3. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
4. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
[TBL] [Abstract][Full Text] [Related]
6. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
Seki JT; Banglawala S; Lentz EM; Reece DE
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
[No Abstract] [Full Text] [Related]
7. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
9. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
Dasanu CA; Bockorny B; Alexandrescu DT
J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide, a thalidomide derivative, shows promise in various applications.
Oestreicher P
ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
[No Abstract] [Full Text] [Related]
11. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
12. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Mariz JM; Esteves GV
Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study.
Briani C; Torre CD; Campagnolo M; Lucchetta M; Berno T; Candiotto L; Padua L; Ermani M; Cavaletti G; Zambello R
J Peripher Nerv Syst; 2013 Mar; 18(1):19-24. PubMed ID: 23521639
[TBL] [Abstract][Full Text] [Related]
14. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
Dasanu CA; Alexandrescu DT
Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
[TBL] [Abstract][Full Text] [Related]
15. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide in the treatment of multiple myeloma: a review.
Armoiry X; Aulagner G; Facon T
J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients.
Guglielmelli T; Petrucci MT; Saglio G; Palumbo A
Br J Haematol; 2011 Jan; 152(1):108-10. PubMed ID: 21083653
[No Abstract] [Full Text] [Related]
19. Reversible pulmonary toxicity due to lenalidomide.
Coates S; Barker A; Spurgeon S
J Oncol Pharm Pract; 2012 Jun; 18(2):284-6. PubMed ID: 21742815
[TBL] [Abstract][Full Text] [Related]
20. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]